Event Brief
Novartis cholesterol drug trial failure triggers selloff
By The BriefBrief · Sources (2)
Filed: Sep 08, 2026 at 11:02 AM ET
Summary: Novartis’s failed trial of a cholesterol drug aimed at lowering Lp(a) contributed to a broad selloff in biopharma stocks, alongside other drugmakers. The article links the market reaction to bets that reducing Lp(a) would cut the risk of certain fatal cardiovascular events.
WHO: Novartis
WHAT: Novartis’s cholesterol drug trial failed, contributing to a broad selloff in biopharma stocks.
WHEN: Sep 08, 2026 at 10:37 AM ET
WHERE: Location not specified
WHY: The selloff followed the failed trial results for a cholesterol drug targeting Lp(a), undermining the drugmakers’ Lp(a)-reduction strategy tied to cardiovascular risk.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
NATS technical issue disrupts departing flights at UK airports
Nats
Sep 08, 2026 at 11:04 AM ET
🔒
Republicans hold first-ever midterm convention in Texas
Us
Sep 08, 2026 at 11:02 AM ET
🔒
Patrick Clancy’s lawyer threatens conspiracy theorists
Us
Sep 08, 2026 at 11:02 AM ET
🔒
Goldman warns oil prices could reach $120
Goldman Sachs
Sep 08, 2026 at 11:02 AM ET
🔒
